BRIEF-Cleveland BioLabs receives FDA advice letter on Entolimod

Oct 1 (Reuters) - Cleveland BioLabs Inc :

* Receives FDA meeting minutes and advice letter on clinical protocol for

development of Entolimod(TM) (cblb502) as radiation countermeasure

* Says the minutes reiterated the FDA's commitment to moving the Entolimod(TM)

program forward

* Minutes summarized FDA's responses and requests regarding several aspects of

plan for dose conversion

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))